---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-035123"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:18:23.054114+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics receives FDA approval for ninth plasma collection center in Dallas, GA

## Summary
- FDA approved Dallas, GA facility's BLA; center began plasma collection in Q3 2022.
- Facility now licensed to collect and ship source plasma interstate for manufacturing.
- Company on track to have all 10 centers FDA-licensed by year-end 2023.
- Supports plasma self-sufficiency, revenue growth, and profitability outlook.
- Facility features Haemonetics NexSys Persona system; expects staff of 50 at capacity.

## SEC filing metadata
- accession: 0001140361-23-035123
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036123035123/0001140361-23-035123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036123035123/brhc20056054_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-035123
- JSON: https://secwatch.observer/filing/0001140361-23-035123.json
- Plain text: https://secwatch.observer/filing/0001140361-23-035123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.